United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
| Revenue (Most Recent Fiscal Year) | $2.88B |
| Net Income (Most Recent Fiscal Year) | $1.20B |
| PE Ratio (Current Year Earnings Estimate) | 11.51 |
| PE Ratio (Trailing 12 Months) | 11.99 |
| PEG Ratio (Long Term Growth Estimate) | 4.66 |
| Price to Sales Ratio (Trailing 12 Months) | 4.50 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.82 |
| Pre-Tax Margin (Trailing 12 Months) | 52.54% |
| Net Margin (Trailing 12 Months) | 40.36% |
| Return on Equity (Trailing 12 Months) | 18.73% |
| Return on Assets (Trailing 12 Months) | 16.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.12 |
| Book Value per Share (Most Recent Fiscal Quarter) | $159.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $6.41 |
| Earnings per Share (Most Recent Fiscal Year) | $24.64 |
| Diluted Earnings per Share (Trailing 12 Months) | $25.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.11M |
| Free Float | 40.46M |
| Market Capitalization | $13.86B |
| Average Volume (Last 20 Days) | 0.80M |
| Beta (Past 60 Months) | 0.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |